CN104725429A - Synthesis method and application of complex Mn(H2L3)2 with anti-tumor activity - Google Patents
Synthesis method and application of complex Mn(H2L3)2 with anti-tumor activity Download PDFInfo
- Publication number
- CN104725429A CN104725429A CN201510071714.6A CN201510071714A CN104725429A CN 104725429 A CN104725429 A CN 104725429A CN 201510071714 A CN201510071714 A CN 201510071714A CN 104725429 A CN104725429 A CN 104725429A
- Authority
- CN
- China
- Prior art keywords
- title complex
- analytically pure
- synthesis method
- complex
- room temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 5
- 238000001308 synthesis method Methods 0.000 title abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 10
- FABVMBDCVAJXMB-UHFFFAOYSA-N 3,5-dichloro-2-hydroxybenzaldehyde Chemical compound OC1=C(Cl)C=C(Cl)C=C1C=O FABVMBDCVAJXMB-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000012153 distilled water Substances 0.000 claims abstract description 4
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 3
- 239000013078 crystal Substances 0.000 claims description 9
- 229960000935 dehydrated alcohol Drugs 0.000 claims description 9
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 claims description 6
- 230000001093 anti-cancer Effects 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 238000013461 design Methods 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 238000010189 synthetic method Methods 0.000 claims description 3
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 2
- 239000011572 manganese Substances 0.000 abstract 4
- 238000013019 agitation Methods 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 229940082328 manganese acetate tetrahydrate Drugs 0.000 abstract 1
- CESXSDZNZGSWSP-UHFFFAOYSA-L manganese(2+);diacetate;tetrahydrate Chemical compound O.O.O.O.[Mn+2].CC([O-])=O.CC([O-])=O CESXSDZNZGSWSP-UHFFFAOYSA-L 0.000 abstract 1
- 239000011259 mixed solution Substances 0.000 abstract 1
- 238000010992 reflux Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- 210000004881 tumor cell Anatomy 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 201000007270 liver cancer Diseases 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 201000005112 urinary bladder cancer Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 239000002262 Schiff base Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- SMQUZDBALVYZAC-UHFFFAOYSA-N salicylaldehyde Chemical compound OC1=CC=CC=C1C=O SMQUZDBALVYZAC-UHFFFAOYSA-N 0.000 description 1
- -1 salicylic aldehyde Schiff bases Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F13/00—Compounds containing elements of Groups 7 or 17 of the Periodic Table
- C07F13/005—Compounds without a metal-carbon linkage
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a synthesis method and an application of a complex Mn(H2L3)2 with anti-tumor activity. Mn(H2L3)2 is characterized in that the molecular formula of Mn(H2L3)2 is C22H24Cl4MnN2O6, and the molecular weight is 609.17. The synthesis method comprises the steps that (1) 1.91g of analytically pure 3,5-dichloro salicylaldehyde is placed in a three-mouth flask, and mixed with 15ml of absolute ethyl alcohol, 1.051g of analytically pure 2-amido-2-methyl-1,3-propylene glycol and 10ml of absolute ethyl alcohol are added, heated, subjected to reflux agitation, cooled, and crystallized, and stood, and H3L3(H3L3=2-((3,5-dichloro-2-hydroxybenzmethylene) amido)-2-methyl-1,3-propylene glycol) is obtained; (2) 0.139g of H3L3 and 0.245g of analytically pure manganese acetate tetrahydrate are dissolved in 15-20ml of mixed solution of absolute ethyl alcohol and self-made distilled water with the volume ratio of 5:5; and (3) the formed solution in the step (2) is transferred to a reaction kettle, reacts, and is cooled, filtered and crystallized. Mn(H2L3)2 can serve as an anti-tumor drug to be applied; the synthesis method is simple in process, low in cost, good in repeatability and high in yield; and chemical constituents are easy to control.
Description
Technical field
The present invention relates to a kind of title complex Mn (H with anticancer activity
2l
3)
2synthesis and application.
Background technology
Recent study finds that salicylic aldehyde Schiff bases title complex has good antibacterial, anti-inflammatory, the biological activity such as antitumor, the synthesis of salicylic aldehyde presence of Schiff-base complex and bioactive research thereof have become the important topic of pharmaceutical chemistry, biologist's research, for social development and technical progress play the effect become more and more important.Particularly in short supply present of efficient new drug, the medicine of exploitation tool high anti-cancer activity solves one of efficient new drug problem method in short supply.Title complex Mn (H
2l
3)
2there is unique biological activity, low toxicity that design and synthesis has the application prospect medicine such as antibacterial, antitumor efficiently can be used as, there is potential use.
Summary of the invention
Object of the present invention is exactly be design and synthesis title complex Mn with anticancer activity (H
2l
3)
2, utilize solvent structure title complex Mn (H
2l
3)
2and as the application of antitumor drug.
Title complex Mn (the H that the present invention relates to
2l
3)
2molecular formula be: C
22h
24cl
4mnN
2o
6, molecular weight is: 609.17, and crystal structural data is in table one, and bond distance's bond angle data are in table two.All restraining effect is had to human hepatoma cell strain (BEL-7404), human liver cancer cell (HepG2), cervical cancer cell (HeLa), human bladder cancer cell (T-24) and normal liver cell's strain (HL-7702) growth of tumour cell.
Table one: Mn (H
2l
3)
2crystallographic parameter
Table two: Mn (H
2l
3)
2's
with bond angle (°)
Mn1–O2 | 2.0253(18) | Mn1–N2 | 2.096(2) |
Mn1–O3 | 1.8638(17) | Mn1–N1 | 2.015(2) |
Mn1–O1 | 1.9040(17) | Mn1–O4 | 2.336(2) |
O3–Mn1–O2 | 93.14(9) | N1–Mn1–O1 | 90.12(8) |
O1–Mn1–O2 | 91.78(8) | N1–Mn1–N2 | 165.44(8) |
O1–Mn1–O3 | 172.17(8) | O4–Mn1–O2 | 162.62(8) |
N2–Mn1–O2 | 87.53(7) | O4–Mn1–O3 | 88.23(8) |
N2–Mn1–O3 | 91.75(8) | O4–Mn1–O1 | 88.89(8) |
N2–Mn1–O1 | 94.55(8) | O4–Mn1–N2 | 75.10(7) |
N1–Mn1–O2 | 106.13(8) | O4–Mn1–N1 | 91.24(8) |
N1–Mn1–O3 | 82.66(8) |
Described title complex Mn (H
2l
3)
2synthetic method concrete steps be:
(1) by analytically pure for 1.91g 3,5-dichloro-salicylaldehyde is placed in there-necked flask, the dehydrated alcohol heated and stirred adding 15ml treats that it dissolves completely, then the analytically pure 2-amino-2-methyl-1 of 1.051g is added, ammediol, then the dehydrated alcohol adding 10ml, heating in water bath, design temperature is 65 DEG C, return stirring about 120 minutes; The solution obtained cools under room temperature, crystallization of naturally volatilizing, and leaves standstill after 3 days, obtains yellow bulk crystals H
3l
3(H
3l
3=2-((3,5 two chloro-2-phenol methylene) is amino)-2-methyl isophthalic acid, ammediol).
(2) 0.139 gram of H step (1) synthesized
3l
315-20 ml volumes is dissolved in than being the dehydrated alcohol of 5:5 and making by oneself in the mixing solutions of distilled water with 0.245 gram of analytical pure four water manganous acetate.
(3) solution obtained by step (2) is proceeded in the reactor of tetrafluoroethylene, react 120 hours at 80-90 DEG C, be cooled to room temperature, filter, filtrate is volatilized under being placed in room temperature crystallization naturally, obtains monocrystalline level title complex Mn (H after 10 days
2l
3)
2; Title complex Mn (H is measured by single crystal diffractometer
2l
3)
2structure.
The present invention has that technique is simple, with low cost, chemical composition is easy to control, reproducible and output advantages of higher.
Accompanying drawing explanation
Fig. 1 is part H of the present invention
3l
3enforcement figure.
Fig. 2 is title complex Mn (H of the present invention
2l
3)
2enforcement figure.
Fig. 3 is title complex Mn (H of the present invention
2l
3)
2structure iron.
Fig. 4 is title complex Mn (H of the present invention
2l
3)
2three-dimensional structure accumulation graph.
Embodiment
Embodiment:
Title complex Mn (the H that the present invention relates to
2l
3)
2molecular formula be: C
22h
24cl
4mnN
2o
6, molecular weight is: 609.17, and crystal structural data is in table one, and bond distance's bond angle data are in table two.
Title complex Mn (H
2l
3)
2synthetic method concrete steps be:
(1) by analytically pure for 1.91g 3,5 dichloro-salicylaldehydes are placed in there-necked flask, the dehydrated alcohol heated and stirred adding 15ml treats that it dissolves completely, then the analytically pure 2-amino-2-methyl-1 of 1.051g is added, ammediol, then the dehydrated alcohol adding 10ml, heating in water bath, design temperature is 65 DEG C, return stirring about 120 minutes.The solution obtained cools under room temperature, crystallization of naturally volatilizing, and leaves standstill after 3 days, obtains yellow bulk crystals H
3l
3(H
3l
3=2-((the chloro-2-phenol methylene of 3,5-bis-) is amino)-2-methyl isophthalic acid, ammediol).
(2) 0.139 gram of H step (1) synthesized
3l
315-20 ml volumes is dissolved in than being the dehydrated alcohol of 5:5 and making by oneself in the mixing solutions of distilled water with 0.245 gram of analytical pure four water manganous acetate.
(3) solution obtained by step (2) is proceeded in the reactor of tetrafluoroethylene, react 120 hours at 80-90 DEG C, be cooled to room temperature, filter, filtrate is volatilized under being placed in room temperature crystallization naturally, obtains monocrystalline level title complex Mn (H after 10 days
2l
3)
2; Title complex Mn (H is measured by single crystal diffractometer
2l
3)
2structure.
Title complex Mn (H with anticancer activity
2l
3)
2the proliferation inhibition activity of various human tumor cell line is tested:
(1) cell strain and cell cultures:
Human hepatoma cell strain (BEL-7404) is selected in this experiment, human liver cancer cell (HepG2), cervical cancer cell (HeLa), human bladder cancer cell (T-24), 5 kinds of human cell lines such as normal liver cell's strain (HL-7702).All cells strain is all cultivated in the RPMI-1640 nutrient solution containing 10wt% calf serum, 100U/mL penicillin, 100U/mL Streptomycin sulphate, puts 37 DEG C containing volumetric concentration 5%CO
2cultivate in incubator.
(2) preparation of testing compound:
Title complex Mn (H used
2l
3)
2purity>=95%, will its DMSO liquid storage physiological buffer dilute after be mixed with the whole solution of 20 μm of ol/L, wherein final concentration≤1% of solubility promoter DMSO, under testing this concentration, compound is to the suppression degree of various growth of tumour cell.
(3) cell growth inhibition test (mtt assay):
1) tumour cell of taking the logarithm vegetative period, after tryptic digestion, the cell suspension that concentration is 5000/ml is mixed with the nutrient solution containing 10% calf serum, be inoculated in 96 well culture plates with every hole 190 μ l, make hole, cell density to 1000 ~ 10000 to be measured (the aseptic PBS of marginal pore fills);
2) 5%CO
2, hatch 24 hours for 37 DEG C, be paved with at the bottom of hole to cell monolayer, every hole adds the medicine 10 μ L of finite concentration gradient, and each concentration gradient establishes 4 multiple holes;
3) 5%CO
2, hatch 48 hours for 37 DEG C, observe under inverted microscope;
4) every hole adds the MTT solution (5mg/mL PBS, i.e. 0.5%MTT) of 10 μ L, continues cultivation 4 hours;
5) stop cultivating, carefully suck nutrient solution in hole, the DMSO that every hole adds 150 μ L fully dissolves first a ceremonial jade-ladle, used in libation precipitation, and after vibrator mixing, be 570nm at microplate reader wavelength, reference wavelength is the optical density value that 450nm measures each hole;
6) zeroing hole (substratum, MTT, DMSO) is set simultaneously, control wells (the medicine dissolution medium of cell, same concentrations, nutrient solution, MTT, DMSO).
7) according to the optical density value (OD value) recorded, judge viable cell quantity, OD value is larger, and cytoactive is stronger.Utilize formula:
Calculate the inhibiting rate of drug on tumor Growth of Cells, then calculate the IC of each test-compound to various human tumor cell line and Human normal hepatocyte strain respectively with Bliss method
50value.
Title complex Mn (H
2l
3)
2to the inhibiting rate of human hepatoma cell strain (BEL-7404), human liver cancer cell (HepG2), cervical cancer cell (HeLa), human bladder cancer cell (T-24) and normal liver cell's strain (HL-7702) growth of tumour cell in table three, to the IC of various human tumor cell line and Human normal hepatocyte strain
50value is in table four.
Table three: Mn (H
2l
3)
2to the inhibiting rate of different cell strain
BEL-7404 | HepG2 | HeLa | T-24 | HL-7702 |
37.18±1.21 | 41.66±0.99 | 51.82±0.91 | 51.98±1.11 | 55.48±1.22 |
Table four: Mn (H
2l
3)
2to the half-inhibition concentration (IC of different cell strain
50, μM)
BEL-7404 | HepG2 | HeLa | T-24 | HL-7702 |
30.22±1.15 | 21.91±1.07 | 13.67±0.88 | 15.35±1.63 | 18.58±1.16 |
Claims (2)
1. a title complex Mn (H with anticancer activity
2l
3)
2, it is characterized in that title complex Mn (H
2l
3)
2molecular formula is: C
22h
24cl
4mnN
2o
6, molecular weight is: 609.17, title complex Mn (H
2l
3)
2have good antitumour activity, crystal structural data is in table one, and bond distance's bond angle data are in table two;
Described title complex Mn (H
2l
3)
2synthetic method concrete steps be:
(1) by analytically pure for 1.91g 3,5-dichloro-salicylaldehyde is placed in there-necked flask, the dehydrated alcohol heated and stirred adding 15ml treats that it dissolves completely, then the analytically pure 2-amino-2-methyl-1 of 1.051g is added, ammediol, then the dehydrated alcohol adding 10ml, heating in water bath, design temperature is 65 DEG C, return stirring 120 minutes; The solution obtained cools under room temperature, crystallization of naturally volatilizing, and leaves standstill after 3 days, obtains yellow bulk crystals H
3l
3, H
3l
3for 2-((the chloro-2-phenol methylene of 3,5-bis-) is amino)-2-methyl isophthalic acid, ammediol;
(2) by H that 0.139 gram of step (1) is synthesized
3l
315-20 ml volumes is dissolved in than being the dehydrated alcohol of 5:5 and making by oneself in the mixing solutions of distilled water with 0.245 gram of analytical pure four water manganous acetate;
(3) solution obtained by step (2) is proceeded in the reactor of tetrafluoroethylene, react 120 hours at 80-90 DEG C, be cooled to room temperature, filter, filtrate is volatilized under being placed in room temperature crystallization naturally, obtains monocrystalline level title complex Mn (H after 10 days
2l
3)
2; Title complex Mn (H is measured by single crystal diffractometer
2l
3)
2structure;
Table one: Mn (H
2l
3)
2crystallographic parameter
Table two: Mn (H
2l
3)
2bond distance
with bond angle (°)
2. title complex title complex Mn (H according to claim 1
2l
3)
2application, it is characterized in that title complex Mn (H
2l
3)
2apply as antitumor drug.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510071714.6A CN104725429A (en) | 2015-02-11 | 2015-02-11 | Synthesis method and application of complex Mn(H2L3)2 with anti-tumor activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510071714.6A CN104725429A (en) | 2015-02-11 | 2015-02-11 | Synthesis method and application of complex Mn(H2L3)2 with anti-tumor activity |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104725429A true CN104725429A (en) | 2015-06-24 |
Family
ID=53449905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510071714.6A Pending CN104725429A (en) | 2015-02-11 | 2015-02-11 | Synthesis method and application of complex Mn(H2L3)2 with anti-tumor activity |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104725429A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106939023A (en) * | 2017-04-01 | 2017-07-11 | 聊城大学 | Manganese ion complex and preparation method and application based on chiral tetrahedron-type metal cluster |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101528673A (en) * | 2006-10-26 | 2009-09-09 | 住友化学株式会社 | Method for producing asymmetric copper complex crystal |
-
2015
- 2015-02-11 CN CN201510071714.6A patent/CN104725429A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101528673A (en) * | 2006-10-26 | 2009-09-09 | 住友化学株式会社 | Method for producing asymmetric copper complex crystal |
Non-Patent Citations (2)
Title |
---|
D.L.PENG: "Synthesis and Crystal Structures of Manganese(IV) Complexes with Tridentate Schiff Bases", 《RUSSIAN JOURNAL OF COORDINATION CHEMISTRY》 * |
ERNEST M. HODNETT ET AL.: "Schiff Bases of Salicylaldehyde and Their Cobalt(II) Derivatives as Anititumor Agents", 《PROCEEDINGS OF THE OKLAHOMA ACADEMY OF SCIENCE》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106939023A (en) * | 2017-04-01 | 2017-07-11 | 聊城大学 | Manganese ion complex and preparation method and application based on chiral tetrahedron-type metal cluster |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104558093A (en) | C21 steroid saponin aglycone derivative as well as preparation method and application thereof in preparing anti-tumor drugs | |
CN104650121A (en) | Synthesis method and application of complex [Zn(H2L2)2](H2O)5 with anticancer activity | |
CN106432190A (en) | A class of 2-aminopyrimidine-containing naphthalimide compounds, preparation method and applications thereof | |
CN110330534B (en) | Novel 2-phenylpyridine-platinum (IV) precursor anticancer complex and synthesis method and application thereof | |
CN105693636B (en) | The synthesis and application of 2 (H2O) 2 of Cu (mtyp) with anticancer activity | |
CN103509046B (en) | Two [three (2-methyl-2-phenyl propyl) tin] dicarboxylic esters and preparation method and application | |
CN105622574B (en) | 3- benzimidazolyl-2 radicals (1H)-qualone derivative and its preparation method and application | |
CN104649930B (en) | Coordination compound with anticancer activity [Zn (H2L4)2].(H2O) synthesis and application | |
CN104910196B (en) | A kind of chiral copper-based organic metal framework of four core and its preparation method and application | |
CN104650157A (en) | Synthesis method and application of a complex [Ni(H2L2)2](H2O)2 with anticancer activity | |
CN103450236A (en) | 6-Hydroxyloxoisoaporphine rare earth complexes, and synthetic method and application thereof | |
CN104725429A (en) | Synthesis method and application of complex Mn(H2L3)2 with anti-tumor activity | |
CN104447397B (en) | The synthesis of 3,5-Dibromosalicylaldehyde contracting AMPD schiff bases with anticancer activity and application | |
CN107501303B (en) | Copper (II) complex and its synthetic method and application that a kind of brufen and quinoline-8-formaldehyde schiff bases are constructed | |
CN104447766A (en) | In-situ synthesis method of complex [Cu2(L<12>)2].(H2O) and antitumor application thereof | |
CN104649931A (en) | Synthesis method and application of complex Mn(H2L4)2 with anticancer activity | |
CN104402761B (en) | Synthesis and application of 2(ethoxy salicyl aldolase-2-amino-2-methyl-1,3-propanediol Schiff base) ethanol | |
CN104447399A (en) | Synthesis and application of methoxysalicylaldehyde 2-amino-2-methyl-1,3-propanediol Schiff base having antitumor activity | |
CN104402762B (en) | The synthesis of with anticancer activity 3,5-dichloro-salicylaldehyde's contracting AMPD schiff bases and application | |
CN104447398A (en) | Synthesis and application of 5-bromosalicylaldehyde 2-amino-2-methyl-1,3-propanediol Schiff base having antitumor activity | |
CN102875462A (en) | Anti-tumor 2-amino nicotinonitrile, application and preparation method thereof | |
CN104387423A (en) | Platinum (II) complex by taking chiral compound as ligand as well as synthetic method and application of platinum (II) complex | |
CN104447875A (en) | Ruthenium (II) complex using chiral compound as ligand as well as synthesis method and application of Ruthenium (II) complex | |
CN104447817B (en) | A kind of coordination compound [[Cu2(L7)(L10)] fabricated in situ and as the application of cancer therapy drug | |
CN104530098A (en) | Synthetic method of monocrystal scale [Cu2(L11)2].(H2O) complex and application of complex as anti-tumor drug |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150624 |
|
WD01 | Invention patent application deemed withdrawn after publication |